Open Access

Long term results of radiotherapy in vulvar cancer patients in Slovenia between 1997–2004


Cite

Figure 1

Local control for the group A (primary operated patients), B (primary irradiated patients), C (patients with relapse) and all patients.
Local control for the group A (primary operated patients), B (primary irradiated patients), C (patients with relapse) and all patients.

Figure 2

Overall survival for the group A, (primary operated patients), B (primary irradiated patients), C (patients with relapse) and all patients.
Overall survival for the group A, (primary operated patients), B (primary irradiated patients), C (patients with relapse) and all patients.

Figure 3

Number of patients with the dose applied to the positive lymph nodes, nodes with extracapsular lymph node extension (ECE) and large tumours.
Number of patients with the dose applied to the positive lymph nodes, nodes with extracapsular lymph node extension (ECE) and large tumours.

Figure 4

The influence of extracapsular nodal extension on local control (p = 0.02).
The influence of extracapsular nodal extension on local control (p = 0.02).

Figure 5

The influence of positive nodes on local control (p = 0.03).
The influence of positive nodes on local control (p = 0.03).

Patients, tumor and treatment characteristcs

characteristicsAllPrimary operatedPrimary irradiatedRelapse group
group Agroup BC
Number of patients (%)56 (100.0%)31 (55.4%)11 (19.6%)14 (25%)
Mean age (years) (+/-SD)74.4 (+/-9.7)74.9 ( +/- 9.8)67.9 (+/-10.8)87.2 (+/- 6.1)
Median follow-up time (months)22.5 (2-203)27 (8-203)9 (2-72)44 (5-134)
FIGO stage
   i5 (8.9%)005 (35.7%)
   ii4 (7.1%)004 (28.6%)
   iii33 (58.9%)23 (74.2%)6 (54.5%)4 (28.6%)
   IV11 (19.6%)7 (22.6%)4 (36.4%)0
   not specified3 (5.4%)1 (3.2%)1 (9.1%)1 (7.1%)
histopathologic grade
   G121 (37.5%)11 (35.5%)3 (27.3%)7 (50.0%)
   G225 (44.6%)15 (48.4)7 (63.6%)3 (21.4%)
   G35 (8.9%)3 (9.7%)1 (9.1%)1 (7.1%)
   not specified5 (8.9%)2 (6.5%)03 (21.4%)
T stage
   T15 (8.9%)2 (6.5%)03 (21.4%)
   T226 (46.4%)18 (58.1%)1 (9.1%)7 (50.0%)
   T316 (28.6%)9 (29.0%)7 (63.6%)0
   T43 (5.4%)1 (3.2%)2 (18.2%)0
   not specified6 (10.7%)1 (3.2%)1 (9.1%)4 (28.6%)
Diameter of primary tumor
   ≤ 2 cm10 (17.9%)7 (22.6%)03 (21.4%)
   > 2 and ≤ 4 cm23 (41.1%)16 (51.6%)3 (27.3%)4 (28.6%)
   > 4 cm12 (21.5%)5 (16.2%)6 (54.5%)1 (7.1%)
   not specified11 (19.6%)3 (9.7%)2 (18.2%)6 (42.9%)
Tumor invasion
   lower urethra9 (16.1%)3 (9.7%)6 (54.5%)0
   vagina15 (26.8%)8 (25.8%)7 (63.6%)0
   anus1 (1.8%)01 (9.1%)0
   bladder wall001 (9.1%)0
   rectal wall1 (1.8%)01 (9.1%)0
   pelvic bone2 (7.1%)1 (3.2%)1 (9.1%)0
Tumor location
   clitoris6 (10.7%)4 (12.9%)02 (14.3%)
   labium major10 (17.9%)5 (16.1%)1 (9.1%)4 (28.6%)
   labium minor8 (14.3%)4 (12.9%)04 (28.6%)
   comissura/more than one location28 (50.0%)16 (51.6%)10 (90.9%)2 (14.3%)
   not specified4 (7.1%)2 (6.5%)02 (14.3%)
Nodal status
   N017 (30.3%)4 (12.9%)5 (45.5%)8 (57.1%)
   N125 (44.6%)19 (61.3%)2 (18.2%)4 (28.6%)
   N210 (17.9%)7 (22.6%)3 (27.3%)0
   not specified4 (7.1%)1 (3.2%)1 (9.1%)2 (14.3%)
Nodal metastases
   micrometastases9 (16.1%)7 (22.6%)not specified2 (14.3%)
   macrometastases25 (44.6%)18 (58.1%)5 (45.5%)2 (14.3%)
Exstracapsular tumor spread
   positive10 (17.9%)8 (25.8%)not specified2 (14.3%)
Residual tumor after surgery20 (35.7%)16 (51.6%)not specified4 (28.6%)
   primary tumor site15 (26.8%)13 (41.9%)not specified2 (14.3%)
   nodal site7 (12.5%)4 (12.9%)not specified3 (21.4%)
Mean dose to the tumor (Gy) (+/-SD)47.4 (+/-7.9)47.1 (+/-8.2)46.7 (+/-8.7)46.0 (+/-5.2)
Mean dose to the inguinofemoral area (Gy) (+/-SD)
   ipsilateral47.5 (+/-8.8)50.7 (+/-7.9)46.9 (+/-8.4)40.1 (+/-6.7)
   contralateral49.7 (+/-9.7)53.4 (+/-7.8)44.9 (+/-9.8)37.4 (+/-6.9)
Mean dose to the pelvic area (Gy) (+/-SD)
   ipsilateral46.2 (+/-6.2)47.0 (+/-6.8)45.0 (+/-4.9)43.5 (+/-6.2)
   contralateral44.6 (+/-10.5)44.7 (+/-12.5)45.0 (+/-4.9)39.1 (+/-4.9)

Pattern of failure at the time of last follow-up

AllPrimary operatedPrimary irradiatedRelapse group
group Agroup BC
Local failure9540
Inguinal failure6312
Distant failure5311
Local and inguinal failure10532
Local/inguinal and distant failure5212
Overall failure3518107
No evidence of disease211317
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Radiology, Internal Medicine, Haematology, Oncology